MoBiosD is a webpage-based Hub, which serves as a central framework to connect many research topics and permit to dock the main results of researchers affiliated to the CAMD-BIR International network. This virtual pocket handles, amplifies and transmits several research frames. This hub guarantees access to suites of integrative Chem-Bio-Med-Informatics applications (open source software and open access, all resources developed by our teams are free!!!) and covers different areas using modern molecular (drug/material/vaccine/biomarker, etc.) design methods (to support this wet-dry cycle).
CAMD-BIR International is devoted to the development of novel computational methods for handling chemical, biological and medical information, database mining for hit and lead compounds, and the generation of pharmacophore models for the design of new bio-active compounds. Some in-house software systems to address the needs of today’s research disciplines including QSAR/QSPR studies, protein modeling, structure and ligand-based design, high throughput discovery, molecular modeling and simulations, Virtual Molecular Screening (mining HTS and eHTS data for compound selection).
Currently, one of core strengths of CAMD-BIR International is in the definition of new molecular and bio-macro-molecular descriptors and the biosilico discovery of novel chemical entities (NCE) as well as early pharmacokinetics (ADME), PhysChem and toxicity prediction. In addition, it is leveraging its know-how and proprietary technology to expand its research activities in the area of docking and scoring functions, protein-protein interactions, synthesis driven combinatorial library design and prediction of the viability of synthetic routes for chemical compounds. We also aim to use in silico technology (namely, approaches based on machine learning and specialized pattern recognition techniques) for medical and pharmaceutical applications such as prediction of drug targets and drug side effects in the chemogenomics and pharmacogenomics framework and prediction of new drug indications for “drug repositioning”.
